Peter Thompson Sells 2,948 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 2,948 shares of the firm’s stock in a transaction dated Saturday, April 18th. The shares were sold at an average price of $44.52, for a total value of $131,244.96. Following the transaction, the director directly owned 2,964,774 shares in the company, valued at approximately $131,991,738.48. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 3.4%

Shares of NASDAQ SION opened at $43.20 on Thursday. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -22.15 and a beta of 3.01. Sionna Therapeutics, Inc. has a 1-year low of $10.97 and a 1-year high of $46.46. The stock’s 50-day moving average is $38.07 and its 200 day moving average is $38.66.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. On average, analysts forecast that Sionna Therapeutics, Inc. will post -2.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Sionna Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. bought a new position in Sionna Therapeutics during the 4th quarter worth approximately $4,573,000. XTX Topco Ltd bought a new position in Sionna Therapeutics during the 4th quarter worth approximately $203,000. Superstring Capital Management LP bought a new position in Sionna Therapeutics during the 4th quarter worth approximately $7,430,000. Artia Global Partners LP bought a new position in Sionna Therapeutics during the 4th quarter worth approximately $4,926,000. Finally, Balyasny Asset Management L.P. bought a new position in Sionna Therapeutics during the 4th quarter worth approximately $58,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SION shares. Raymond James Financial reissued a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Citizens Jmp started coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price objective on the stock. BTIG Research reissued a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.57.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.